Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:529876.
doi: 10.5402/2011/529876. Epub 2011 May 22.

Adjuvant perioperative intraperitoneal chemotherapy in locally advanced colorectal carcinoma: preliminary results

A A K Tentes  1 , I D Spiliotis, O S Korakianitis, A Vaxevanidou, D Kyziridis
Affiliations

Adjuvant perioperative intraperitoneal chemotherapy in locally advanced colorectal carcinoma: preliminary results

A A K Tentes et al. ISRN Surg. 2011.

Abstract

Background and Aims. Intraperitoneal chemotherapy is a basic tool in the treatment of peritoneal malignancy. The purpose of the study is to investigate the effect of adjuvant perioperative intraperitoneal chemotherapy in the treatment of locally advanced colorectal cancer. Patients and Methods. Patients with T(3) and T(4) colorectal carcinomas that underwent R(0) resection received either hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC group = 40 patients) or early postoperative intraperitoneal chemotherapy (EPIC group = 67 patients). The survival, the recurrences and the sites of recurrence were assessed. Results. The 3-year survival rate for HIPEC group was 100% and for EPIC group 69% (P = .011). Nodal infiltration was found to be the single prognostic indicator of survival. The incidence of recurrence in EPIC group was higher than in HIPEC group (P = .009). The independent indicators of recurrence were the use of HIPEC and the degree of differentiation (P < .05). Conclusions. Intraperitoneal chemotherapy, particularly HIPEC, as an adjuvant in locally advanced colorectal carcinomas appears to improve survival and decrease the incidence of recurrence.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival according to type of intraperitoneal chemotherapy (continuous line-HIPEC-group, dotted line = EPIC group).
See this image and copyright information in PMC

References

    1. Galandiuk S, Wieand HS, Moertel CG, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surgery Gynecology and Obstetrics. 1992;174(1):27–32. - PubMed
    1. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. Journal of the National Cancer Institute. 2001;93(8):583–596. - PubMed
    1. MacFarlane JK, Ryall RDH, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341(8843):457–460. - PubMed
    1. Tentes AAK, Mirelis C, Karanikiotis C, Korakianitis O. Radical lymph node resection of the retroperitoneal area for left-sided colon cancer. Langenbeck’s Archives of Surgery. 2007;392(2):155–160. - PubMed
    1. August DA, Ottow RT, Sugarbaker PH. Clinical perspective of human colorectal cancer metastasis. Cancer and Metastasis Review. 1984;3(4):303–324. - PubMed

LinkOut - more resources